A multi-omics study demonstrates that FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer. These findings highlight a vulnerability to mitochondrial inhibitors as a precision therapy for FGFR3-altered tumours.
- Giacomo Ducci
- Giorgia Ciufolini
- Elena Sacco
